文献速递炎症性肠病消化道肿瘤与早癌消化内镜

瑞典炎症性肠病人群结肠镜检查后结直肠癌的发生率与特征:与非炎症性肠病人群的差异

Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?
PubMed 文献 · Gut · 2018-12-15

基于瑞典2001至2010年人群的队列研究,共纳入348232次结肠镜检查。CD组结肠镜检查后结直肠癌(PCCRC)率为28.3%,UC组为41.0%;与非IBD相比,CD的RR为3.82(95%CI 2.94至4.96),UC的RR为5.89(95%CI 5.10至6.80)。CD直肠癌部位和UC年轻患者风险最高。

要点

  • CD组PCCRC率为28.3%,UC组为41.0%。
  • 与非IBD相比,CD的RR为3.82(95%CI 2.94至4.96),UC为5.89(95%CI 5.10至6.80)。
  • CD直肠癌部位和UC年轻患者PCCRC风险最高。

核心结论

  • 年轻UC患者和CD直肠癌部位的高PCCRC率可能影响未来IBD监测的实施。

研究设计与样本

  • 2001至2010年瑞典基于人群的结肠镜检查队列研究,共348232次结肠镜检查、270918人;CD组14597人共27123次检查,UC组26513人共51572次检查。

主要发现

  • 非IBD组结直肠癌13317例,CD组133例,UC组281例。
  • CD组PCCRC率为28.3%,UC组为41.0%。
  • 与非IBD相比,CD的RR为3.82(95%CI 2.94至4.96),UC的RR为5.89(95%CI 5.10至6.80)。
  • CD直肠癌部位和UC年轻患者中观察到最高风险。

关键数值与推荐

  • PCCRC定义为结肠镜检查后6至36个月检测到的结直肠癌,dCRC为0至6个月。
  • PCCRC率计算公式为假阴性数除以(真阳性数加假阴性数)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The rate of postcolonoscopy colorectal cancer (PCCRC) is considered a key quality indicator of colonoscopy; little is known about PCCRC in IBD. DESIGN: A population-based cohort study of colonoscopies in Sweden from 2001 to 2010 was conducted. Individuals with a colorectal cancer (CRC) detected within 36 months after a colonoscopy were identified and stratified on UC, Crohn's disease (CD) or non-IBD. The CRCs were classified as detected CRCs (dCRC) (0-6 months) or as PCCRCs (6-36 months). PCCRC rates were calculated by the number of false negative/(the number of true positive+the number of false negative) colonoscopies. Poisson regression analysis was employed to examine the association between PCCRC and IBD (CD and UC) diagnosis, age, gender, location, time period and comorbidities. RESULTS: We identified 348 232 colonoscopies in 270 918 individuals. Of these, 27 123 were performed on 14 597 individuals with CD, and 51 572 were performed on 26 513 individuals with UC. There were 13 317 CRCs in the non-IBD group, 133 in the CD group and 281 in the UC group. The PCCRC rate in the CD group was 28.3% and 41.0% in the UC group. The RR for a PCCRC was 3.82 (95% CI 2.94 to 4.96) in CD and 5.89 (95% CI 5.10 to 6.80) in UC, compared with non-IBD. The highest risk was observed among rectal cancer location in CD and in younger individuals with UC. CONCLUSION: The high rates of PCCRC in young patients with UC and for rectal cancer location in CD might affect future performance of IBD surveillance.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Stjärngrim J, Ekbom A, Hammar U, et al. Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population? Gut. 2018. PMID: 30554159. doi:10.1136/gutjnl-2018-316651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。